Neos Therapeutics to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017

DALLAS and FORT WORTH, Texas, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. NEOS, a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that it will report its second quarter 2017 financial results prior to the opening of U.S. financial markets on Tuesday, August 8, 2017. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.

The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 51584953. A live audio webcast for the conference call will be available on the Investor Relations page of the company's website at http://investors.neostx.com/.

About Neos Therapeutics

Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT^TM, indicated for the treatment of ADHD in patients 6 years of age and older, and Cotempla XR-ODT^TM, indicated for the treatment of ADHD in patients 6 to 17 years old, are the first approved products using the Company's extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the U.S. Food and Drug Administration for one other branded product candidate that is an XR medication in oral suspension dosage form. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex^®, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.

Contacts:

Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com

Sarah McCabe
Vice President
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com